Advertisement
YOU ARE HERE: LAT HomeCollectionsGeneric Brands
IN THE NEWS

Generic Brands

BUSINESS
July 13, 2006 | From Reuters
A U.S. district judge declined to issue a preliminary injunction blocking two companies from exclusively selling their generic versions of Merck & Co.'s Zocor cholesterol drug. Novartis' Sandoz unit had sought a temporary restraining order against generic manufacturers Teva Pharmaceutical Industries Ltd.'s Ivax and Ranbaxy Laboratories Ltd. U.S.
Advertisement
BUSINESS
July 1, 2006 | From the Associated Press
The first generic versions of Zoloft received federal approval. Israel's Teva Pharmaceutical Industries Ltd. said it would make generic versions of the antidepressant in 25-, 50- and 100-milligram tablets. Roxane Laboratories Inc., based in Columbus, Ohio, would make a liquid concentrate version of the drug, the Food and Drug Administration said. Pfizer Inc.'s patent on Zoloft expires today.
BUSINESS
June 23, 2006 | From Bloomberg News
Aetna Inc. said Thursday that it would buy discounted copies of the cholesterol drug Zocor from Teva Pharmaceutical Industries Ltd. rather than accept an offer from Merck & Co. to sell its branded pill for less than the generic. Aetna patients will pay more out-of-pocket for Merck's Zocor than Teva's generic, Aetna said. Eric Elliott, Aetna's pharmacy manager, said the Hartford, Conn.
BUSINESS
May 26, 2006 | From Bloomberg News
Israel-based Teva Pharmaceutical Industries Ltd. won tentative U.S. regulatory approval to sell copies of Merck & Co.'s Zocor cholesterol drug, and said sales might start in June. Still at issue is the ability of Teva, the world's biggest generic drug maker, to sell the pills exclusively for six months under a U.S. rule designed to promote cheaper generics.
BUSINESS
May 20, 2006 | Daniel Yi, Times Staff Writer
The nation's largest pharmacy benefits manager announced Friday that it was distributing more generic drugs than brand-name counterparts, a sign that costly brand-name prescription medicines may be losing their grip on the market, leading to lower drug costs for consumers. The trend is significant because even more generic prescription drugs are expected to hit the market in the near future.
BUSINESS
April 5, 2006 | From Bloomberg News
When two competing generic drugs come on the market, the average generic price can drop to half the cost of the comparable brand-name product, according to a U.S. government study released Tuesday. The study by the Food and Drug Administration found that savings weren't as significant when only one generic drug was on the market: the price of the generic drug is typically 6% less than the brand-name competition.
BUSINESS
March 7, 2006 | From Bloomberg News
GlaxoSmithKline lost a bid to prevent sales of generic versions of its $900-million-a-year allergy drug Flonase. Boehringer Ingelheim's generic version could reach the market today after U.S. District Judge Andre Davis in Baltimore refused to block sales while Glaxo pursues a lawsuit against the Food and Drug Administration.
BUSINESS
January 4, 2006 | From Bloomberg News
Allergan Inc. said it won a ruling temporarily blocking Apotex Inc. from making or selling a generic version of a treatment for eye inflammation. The ruling, issued Dec. 29 by U.S. District Judge Martin Jenkins in San Francisco, temporarily prohibits Apotex from manufacturing or selling a generic version of Allergan's Acular in the U.S., Allergan spokeswoman Caroline Van Hove said. Irvine-based Allergan, which also makes the anti-wrinkle drug Botox, sued Apotex over patents for Acular in 2001.
BUSINESS
September 7, 2005 | From Associated Press
Barr Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. said they would cooperate in launching generic versions of Sanofi-Aventis' Allegra allergy drug. Barr of Pomona, N.Y., received final approval last week for the generic drug from the Food and Drug Administration. Allegra sales were worth $1.4 billion for the 12 months ended in June, according to research firm IMS Health.
BUSINESS
August 24, 2005 | From Bloomberg News
Generic-drug makers including Ivax Corp. and Teva Pharmaceutical Industries Ltd. aren't infringing patents on Pfizer Inc.'s epilepsy drug Neurontin by selling low-cost versions, a federal judge ruled. U.S. District Judge John Lifland in Newark, N.J., said the generic version of gabapentin, the key ingredient in Neurontin, didn't infringe. Pfizer will appeal, spokesman Paul Fitzhenry said. Teva, Ivax and Alpharma Inc.
Los Angeles Times Articles
|